Chronic kidney disease increases the risk of cardiovascular events associated with type 2 diabetes. A clinical trial sought to discover if finerenone would help patients with both of these conditions.
Using certain glucose inhibitors in people with type 2 diabetes may also have a beneficial effect on renal and cardiovascular health, and weight.
Greater reduction in glycated hemoglobin levels and improved weight loss seen with tirzepatide in type 2 diabetes
A team of investigators assessed the frequency with which patients with type 2 diabetes and heart failure were prescribed sodium-glucose co-transporter 2 inhibitors.
A team of investigators assessed the frequency with which patients with type 2 diabetes and heart failure were prescribed sodium-glucose co-transporter 2 inhibitors.
A team of investigators sought to identify the impact of hyperglycemia on the severity of and outcomes associated with stroke in patients with type 2 diabetes.
Researchers report the results of a systematic review assessing risk factors for peripheral artery disease in populations with type 2 diabetes.
Researchers sought to determine whether ertugliflozin plus insulin would help redice body weight, systolic blood pressure, HbA1c, and other metrics among individuals with T2DM.
Researchers assessed the risk for obstructive sleep apnea (OSA) among patients with type 2 diabetes and cardiovascular disease taking empagliflozin and further examined the effect of OSA on metabolic, cardiovascular, and renal outcomes.
